These results are consistent with earlier observations that WEE1 and CHK1 expression levels are associated with cisplatin sensitivity [52], and targeting cell-cycle checkpoints, including ATR, CHK1, and WEE1, can be used to sensitize tumor cells to cisplatin. Here, CHEK1 is linked to neoplasm.